

CB2 Insights Inc.

09:10 12 Dec 2019

CB2 Insights set to launch cloud-based platform Sail in 2020

CB2 Insights Inc (CSE:CBII) (OTCMKTS:CBIIIF) is ready to set Sail with its core technology platform aimed at connecting unequal data systems.

The company's core technology, Sail, brings together multiple data references from production, retail, medical and product information into a single platform to help licensed producers or operators to improve efficiencies in data handling.

The data analytics company said that Sail is the cannabis sector's first cannabinoid-focused healthcare data aggregation tool.

READ: CB2 Insights implements incentive program for \$1.1M of outstanding warrants

CB2 plans to launch the cloud-based platform in 2020, the Toronto-based company said in a Thursday statement.

"As is often seen in healthcare, managing multiple, disparate systems is a large and expensive barrier and often leads to failed attempts at making solid business decisions," CEO Prad Sekar told investors. "At CB2 we are committed to be the leading company for streamlining, measuring, and generating insightful data to make improvements for the maturing global medical cannabis industry."

The Sail platform has been used to collect and analyze millions of data points from hundreds of thousands of medical patients using cannabinoid therapy, Sekar said. It is now able to integrate full data inputs from electronic medical record, dispensary, pharmacy systems, and clinical research systems to produce actionable insights, according to the CEO.

"The data lake will integrate a variety of distinct raw data sets sourced from clinical assets, dispensaries, cannabis companies and other key industry suppliers," CB2's chief technical officer Kash Qureshi told shareholders.

"Raw anonymized data will be ingested and catalogued, creating a repository that in turn will be a single source to generate insights which can be reviewed and tested over indefinitely and will be key to improving research projects moving forward."

Earlier this year, CB2 secured technology and data-focused partnerships with Premier Health Group, UK-based Drug Science, MyAccess Clinics, VIVO Cannabis and FCM Global in Colombia.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Price: 0.1

Market Cap: \$8.28 m

1 Year Share Price Graph



Share Information

Code: CBII

Listing: CSE

52 week High Low
0.21 0.055

Sector: Cannabis

Website: cb2insights.com

Company Synopsis:

Our mission is to deliver the industry's most comprehensive, data-driven software and services - transforming the way the global cannabis industry evolves through actionable insights.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).